Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Here are five questions answered about the FDA's decision to halt compounded versions of GLP-1 drugs. The FDA says state-licensed compounding pharmacies must immediately stop making most compound ...

GLP-1 drugs can also erode muscle mass by up to 40% as part of the weight loss process. “Many individuals who discontinue GLP-1 drugs experience rapid weight regain, often without recovering lost ...

In the United States, obesity impacts nearly 42% of adults and nearly 20% of children. It’s the cause of 53% of new cases of Type 2 diabetes each year and is linked to hundreds of medical ...

where they managed to find a much-needed 3-1 victory against the Flyers, who themselves were struggling to halt their own four-game downturn. Adding a spark to the Devils’ effort, Cody Glass ...

Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment. When GLP-1 drugs ...